← Back to Search

Cancer Vaccine

Self-Collection Screening for Cervical Cancer Prevention (Merck-3 Trial)

N/A
Waitlist Available
Research Sponsored by Indiana University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Kenyan girls ages 9 through 14
Kenyan women between the ages of 30 to 55 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to prevent cervical cancer in Kenyan women by combining screening for premalignancies and vaccinating children against HPV. Currently, only a small percentage of women are regularly screened, and very few

Who is the study for?
The trial is for Kenyan girls aged 9-14 ready to consent to HPV vaccination and can return for a second dose, and women aged 30-55 able to visit the Webuye Clinic for cervical screening.
What is being tested?
This program tests self-collection of vaginal swabs in adult women and vaccinates female children against HPV. It aims to improve cervical cancer prevention by overcoming barriers like travel distance, costs, and lack of education.
What are the potential side effects?
While specific side effects are not detailed here, typical reactions may include discomfort at the swab collection site or temporary symptoms following vaccination such as soreness at injection site, mild fever or headache.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a Kenyan girl aged 9 to 14.
Select...
I am a Kenyan woman aged between 30 and 55.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Acceptability rate of the Mother Daughter Program
Secondary study objectives
HPV detection
Other study objectives
HPV detection in genital warts

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: All women and girls eligible for the studyExperimental Treatment1 Intervention
All women and girls eligible for the study. There is no control arm.

Find a Location

Who is running the clinical trial?

Academic Model Providing Access to Healthcare (AMPATH)OTHER
6 Previous Clinical Trials
8,415 Total Patients Enrolled
Indiana UniversityLead Sponsor
1,039 Previous Clinical Trials
1,216,558 Total Patients Enrolled
~1667 spots leftby May 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top